Welcome : Guest

Rising Incidence of Immune Disorders Drives the Intravenous Immunoglobulin (IVIg) Market

Published: August 2017


  • Code: MCP-7776
  • Pages: 187
  • Tables: 72
  • Companies: 24


The global market for Intravenous Immunoglobulin (IVIg) is projected to reach US$15.9 billion by 2024, driven by the rise in the prevalence of immunoglobulin deficiency and autoimmune diseases such as lupus. Against the backdrop of the aging global population and the unique challenges it presents to the healthcare system, efforts are underway to test the efficacy of IVIg therapy in the treatment of Alzheimer’s. The market stands to benefit from the growing investments in researching the efficacy of IVIg treatment in other indications beyond immune-deficiencies and neurology; and rise in clinical trial studies evaluating the effectiveness of IVIg in combination with immunosuppressive drugs and monoclonal antibodies. The United States represents the largest market worldwide, supported by large target patient population and favorable government policies. Asia-Pacific ranks as the fastest growing market with a CAGR of 9.7% through the analysis period led by factors such as growing population and a parallel increase in healthcare burden; developing healthcare infrastructure; rising awareness over the efficacy of plasma protein therapies; and expanding base of middle class population and their propensity to spend for quality healthcare services. 

    Summary of Findings

  • Growing Clinical Evidence of the Effectiveness of Combination IVIg Drives the Popularity of Intravenous Immunoglobulin and Rituximab to Prevent Antibody-Mediated Rejection in Kidney Transplant Patients
  • Well Documented Evidence of Fewer Side Effects Drives Research Interest in the use of Intravenous immunoglobulin (IVIg) in Treating Neurological Diseases
  • Subcutaneous Immunoglobulin (SCIg) Formulation Grow in Popularity over Intravenous Administration Supported by Benefits such as Fewer Systemic Side Effects, Increased Bioavailability and Shorter Administration Times
  • Continued Off-Label Uses of Immune Globulin (IG) in Conditions such as Guillain-Barré Syndrome, Polymyositis, Dermatomyositis, Multifocal Motor Neuropathy to Benefit Market Growth
  • Pending New Approvals in New Disease Indications to Spur Future Growth in the Market

    Timeline for Analysis

  • Market Estimates and Forecasts for 2016-2024
  • Historic Review 2011-2015

    Geographic Markets Analyzed

  • US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific (Australia, China and Rest of Asia-Pacific), and Rest of World


  • Bharat Serums and Vaccines Limited
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.


  • Review of Industry/Market Structure
  • Analysis of Trends & Drivers
  • Insights on Macro Market Scenarios
  • Market SWOT Analysis
  • Latent Demand Forecasts & Projections
  • Comprehensive Geographic Market Analysis
  • Presentation Ready Facts & Statistical Data Findings
  • Coverage of Major/Niche Players, Market Shares & Competition
  • Coverage of major Company/Technology/Product/Financial Stories
  • Extensive Product/Service/End-Use/Technology Coverage Where Applicable

Interested in our research, you can contact our 24/7 Research Support e-Desk at rsd@strategyr.com